Carcinosarcoma of the corpus uteri
MONDO:0016259An aggressive malignant mixed epithelial and mesenchymal tumor that arises from the uterine corpus. It usually affects elderly postmenopausal women and presents with vaginal bleeding. It is characterized by the presence of a malignant epithelial component that is usually glandular and a sarcomatous component.
Also known as: uterine carcinosarcoma, body of uterus carcinosarcoma, carcinosarcoma of corpus uteri, carcinosarcoma of the corpus uteri, carcinosarcoma of the uterine body, carcinosarcoma of the uterine corpus, carcinosarcoma of uterine body, carcinosarcoma of uterine corpus
2853 clinical trials for this condition and its sub-types, 13 tagged with Carcinosarcoma of the corpus uteri itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Targeted therapy boost for aggressive uterine cancer under study
Disease control Recruiting nowThis phase 3 trial tests whether adding targeted drugs (trastuzumab and pertuzumab) to standard chemotherapy can better shrink tumors in people with HER2-positive endometrial cancer. The study plans to enroll 360 participants with various stages of the disease. However, the trial…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 21, 2026 21:00 UTC
-
New drug combo aims to stall endometrial cancer in High-Risk patients
Disease control Recruiting nowThis study tests whether two drugs, abemaciclib and letrozole, can help keep advanced or recurrent endometrial cancer from getting worse. About 32 people with a specific type of estrogen-sensitive cancer will take these pills daily after initial treatment. The goal is to see if t…
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New hope for rare, deadly gynecologic cancers: drug combo trial launches
Disease control Recruiting nowThis clinical trial is testing whether a combination of two drugs—dostarlimab (an immunotherapy) and niraparib (a PARP inhibitor)—works better than standard chemotherapy for women with a rare and aggressive type of uterine or ovarian cancer called carcinosarcoma. The study will e…
Phase 2/3 • Sponsor: ARCAGY/ GINECO GROUP • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New drug cocktail aims to outsmart resistant uterine cancer
Disease control Recruiting nowThis phase 2 trial tests whether combining hormone therapy (letrozole) with a targeted drug (abemaciclib), and possibly adding metformin or gedatolisib, can control estrogen-receptor-positive endometrial cancer that has returned or spread. The study enrolls adults with this cance…
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Digital therapy aims to tame the fear that haunts cancer survivors
Symptom relief Recruiting nowThis trial tests a blended e-health program designed to help women with breast or gynecologic cancer cope with fear of their cancer returning or worsening. The program combines remote group sessions with online modules that teach skills to manage unhelpful thoughts and promote he…
Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated Aug 12, 2026 00:00 UTC
-
Fewer hospital visits for cancer radiation? new trial tests shorter treatment
Symptom relief Recruiting nowThis study is testing whether a shorter course of pelvic radiation after surgery works as well as the standard longer schedule for people with cervical or endometrial cancer. The shorter schedule means fewer hospital visits and less time in treatment. About 120 participants will …
Sponsor: Siriraj Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
Could a shorter radiation course be just as good for endometrial cancer?
Symptom relief Recruiting nowThis study compares a shorter course of vaginal cuff brachytherapy (internal radiation) to the standard longer course for people with stage I-II endometrial cancer. The main goal is to see if the shorter treatment improves quality of life and reduces financial burden, while still…
Phase 3 • Sponsor: University of Utah • Aim: Symptom relief
Last updated Jun 27, 2026 08:03 UTC
-
Blood test may replace needles for endometrial cancer monitoring
Knowledge-focused Recruiting nowThis study is testing whether a blood test, called a liquid biopsy, can find cancer cells and predict if endometrial cancer will return. Researchers will collect blood and tissue samples from 1,000 women with endometrial cancer before and after treatment. The goal is to see if th…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC